Your browser does not support JavaScript or JavaScript has been disabled. Please upgrade to a newer version of the browser or enable JavaScript. You might still be able to use some of the features but some of the useful features use JavaScript. Thank you!
RIC: Research Interest Comparator
PRADEEPKUMAR, Ph.D.
Affiliation: IIT BOMBAY
Email: pradeep@chem.iitb.ac.in
Home Page: http://www.chem.iitb.ac.in/people/Faculty/prof/pradeepkumar.html
New This Month
|
New This Year
|
Abstract
|
Selected Publications
|
RIC Statistics
Results - FULL MEDLINE:
Revertants of adenovirus type 12-transformed hamster cell line T637 as tools in the analysis of integration patterns.
D Eick ... W Doerfler
J Virol 1980 Oct; 36(1)41-9.
Score: 0.857
Grb7-based molecular therapeutics in cancer.
Stephanie C Pero ... David N Krag
Expert Rev Mol Med 2003 May; 5(14)1-11.
Score: 0.831
Evidence for splicing of avian sarcoma virus 5'-terminal genomic sequences into viral-specific RNA in infected cells.
R A Krzyzek ... A J Faras
Proc Natl Acad Sci U S A 1978 Mar; 75(3)1284-8.
Score: 0.795
Strand orientation of simian virus 40 transcription in productively infected cells.
D M Lindstrom ... R Dulbecco
Proc Natl Acad Sci U S A 1972 Jun; 69(6)1517-20.
Score: 0.753
Short interfering RNA (siRNA) as a novel therapeutic.
Peter N Pushparaj ... Alirio J Melendez
Clin Exp Pharmacol Physiol 2006 May-Jun; 33(5-6)504-10.
Score: 0.716
Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Achim Aigner
J Biotechnol 2006 Jun; 124(1)12-25.
Score: 0.672
Targeted gene silencing by small interfering RNA-based knock-down technology.
J Zhang ... Z C Hua
Curr Pharm Biotechnol 2004 Feb; 5(1)1-7.
Score: 0.664
Gene silencing mediated by small interfering RNAs in mammalian cells.
Michaela Scherr ... Matthias Eder
Curr Med Chem 2003 Feb; 10(3)245-56.
Score: 0.653
Calcium-induced dissociation of human plasma factor XIII and the appearance of catalytic activity.
R D Cooke
Biochem J 1974 Sep; 141(3)683-91.
Score: 0.644
RNA interference in pain research.
Thomas Röhl ... Jens Kurreck
J Neurochem 2006 Oct; 99(2)371-80.
Score: 0.639
Mutations of bacteriophage T7 that affect initiation of synthesis of the gene 0.3 protein.
J J Dunn ... F W Studier
Proc Natl Acad Sci U S A 1978 Jun; 75(6)2741-5.
Score: 0.632
G-Quadruplex DNA as a target for drug design.
S M Kerwin
Curr Pharm Des 2000 Mar; 6(4)441-78.
Score: 0.627
RNA interference as a gene-specific approach for molecular medicine.
A Grünweller ... R K Hartmann
Curr Med Chem 2005 ; 12(26)3143-61.
Score: 0.626
Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs.
Derek M Dykxhoorn ... Judy Lieberman
Annu Rev Biomed Eng 2006 ; 8()377-402.
Score: 0.622
On the delivery of small interfering RNAs into mammalian cells.
Mouldy Sioud
Expert Opin Drug Deliv 2005 Jul; 2(4)639-51.
Score: 0.622
siRNA technology.
N Schütze
Mol Cell Endocrinol 2004 Jan; 213(2)115-9.
Score: 0.615
Molecular design and delivery of siRNA.
Atsushi Inoue ... Kazunari Taira
J Drug Target 2006 ; 14(7)448-55.
Score: 0.613
[RNA interference (RNAi) as novel approach for gene silencing--review]
Xiao-Xia Hu
Zhongguo Shi Yan Xue Ye Xue Za Zhi 2005 Dec; 13(6)1141-4.
Score: 0.608
DEQOR: a web-based tool for the design and quality control of siRNAs.
Andreas Henschel ... Bianca Habermann
Nucleic Acids Res 2004 Jul; 32(Web Server issue)W113-20.
Score: 0.604
Ribozymes and siRnas: from structure to preclinical applications.
M Sioud
Handb Exp Pharmacol 2006 ; (173)223-42.
Score: 0.602
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
Daniel De Paula ... Ram I Mahato
RNA 2007 Apr; 13(4)431-56.
Score: 0.600
Short interfering RNA (siRNA): tool or therapeutic?
Daniel Cejka ... Volker Wacheck
Clin Sci (Lond) 2006 Jan; 110(1)47-58.
Score: 0.599
RNA interference by mixtures of siRNAs prepared using custom oligonucleotide arrays.
Andrew V Oleinikov ... Matthew D Gray
Nucleic Acids Res 2005 ; 33(10)e92.
Score: 0.598
Nonviral in vivo delivery of therapeutic small interfering RNAs.
Achim Aigner
Curr Opin Mol Ther 2007 Aug; 9(4)345-52.
Score: 0.597
Single-stranded antisense siRNAs guide target RNA cleavage in RNAi.
Javier Martinez ... Thomas Tuschl
Cell 2002 Sep; 110(5)563-74.
Score: 0.588
Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo.
Achim Aigner
Appl Microbiol Biotechnol 2007 Aug; 76(1)9-21.
Score: 0.586
Enhanced gene silencing by the application of multiple specific small interfering RNAs.
Jingmin Ji ... Peter Erb
FEBS Lett 2003 Sep; 552(2-3)247-52.
Score: 0.585
Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA).
Thomas Dowler ... Masad J Damha
Nucleic Acids Res 2006 ; 34(6)1669-75.
Score: 0.584
siRNA function in RNAi: a chemical modification analysis.
Ya-Lin Chiu ... Tariq M Rana
RNA 2003 Sep; 9(9)1034-48.
Score: 0.583
Antiviral applications of RNAi.
Kevin V Morris ... John J Rossi
Curr Opin Mol Ther 2006 Apr; 8(2)115-21.
Score: 0.583
Gene silencing of HIV-1 by RNA interference.
Hiroshi Takaku
Antivir Chem Chemother 2004 Mar; 15(2)57-65.
Score: 0.581
RNA interference and human disease.
Jerry C Cheng ... Kathleen M Sakamoto
Mol Genet Metab 2003 Sep-Oct; 80(1-2)121-8.
Score: 0.581
siRNA Efficiency: Structure or Sequence-That Is the Question.
Jens Kurreck
J Biomed Biotechnol 2006 ; 2006(4)83757.
Score: 0.580
The function of teichoic acids in cation control in bacterial membranes.
A H Hughes ... J Baddiley
Biochem J 1973 Jan; 132(1)83-93.
Score: 0.580
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate.
S M Elbashir ... T Tuschl
EMBO J 2001 Dec; 20(23)6877-88.
Score: 0.579
Potentiality of small interfering RNAs (siRNA) as recent therapeutic targets for gene-silencing.
Chiranjib Chakraborty
Curr Drug Targets 2007 Mar; 8(3)469-82.
Score: 0.575
Recent applications of RNAi in mammalian systems.
Lisa Scherer ... John J Rossi
Curr Pharm Biotechnol 2004 Aug; 5(4)355-60.
Score: 0.575
An exonuclease I hydrolysis assay for evaluating G-quadruplex stabilization by small molecules.
Yuan Yao ... Zheng Tan
Nucleic Acids Res 2007 ; 35(9)e68.
Score: 0.564
RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics.
Antonin de Fougerolles ... Hans-Peter Vornlocher
Methods Enzymol 2005 ; 392()278-96.
Score: 0.564
The ins and outs of RNAi in mammalian cells.
M Banan ... N Puri
Curr Pharm Biotechnol 2004 Oct; 5(5)441-50.
Score: 0.563
RNA Silencing in the struggle against disease.
Volker Patzel ... Stefan H E Kaufmann
Ann N Y Acad Sci 2006 Oct; 1082()44-6.
Score: 0.561
Small interfering RNA-mediated gene silencing in T lymphocytes.
Michael T McManus ... Phillip A Sharp
J Immunol 2002 Nov; 169(10)5754-60.
Score: 0.560
Altered nucleic acids of antibody-forming tissues.
J R Little ... H A Donahue
Proc Natl Acad Sci U S A 1970 Nov; 67(3)1299-306.
Score: 0.557
Delivery Systems for the Direct Application of siRNAs to Induce RNA Interference (RNAi) In Vivo.
Achim Aigner
J Biomed Biotechnol 2006 ; 2006(4)71659.
Score: 0.556
Antiviral applications of RNAi.
K V Morris ... J J Rossi
Handb Exp Pharmacol 2006 ; (173)105-16.
Score: 0.551
Specific HIV-1 env gene silencing by small interfering RNAs in human peripheral blood mononuclear cells.
W-S Park ... H Takaku
Gene Ther 2003 Nov; 10(24)2046-50.
Score: 0.551
Gene silencing of virus replication by RNA interference.
N Miyano-Kurosaki ... H Takaku
Handb Exp Pharmacol 2006 ; (173)151-71.
Score: 0.549
On the art of identifying effective and specific siRNAs.
Yi Pei ... Thomas Tuschl
Nat Methods 2006 Sep; 3(9)670-6.
Score: 0.548
Control of HIV-1 replication by RNA interference.
Nan Sook Lee ... John J Rossi
Virus Res 2004 Jun; 102(1)53-8.
Score: 0.546
A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells.
Chuan-Fu Hung ... Wen-Tsan Chang
Biochem Biophys Res Commun 2006 Aug; 346(3)707-20.
Score: 0.545
Telomeres and telomerases as drug targets.
Evonne M Rezler ... Laurence H Hurley
Curr Opin Pharmacol 2002 Aug; 2(4)415-23.
Score: 0.545
Design of active small interfering RNAs.
Andrew S Peek ... Mark A Behlke
Curr Opin Mol Ther 2007 Apr; 9(2)110-8.
Score: 0.544
RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase.
Olivier Donzé ... Didier Picard
Nucleic Acids Res 2002 May; 30(10)e46.
Score: 0.544
siRNA--getting the message out.
S H Lee ... P J Sinko
Eur J Pharm Sci 2006 Apr; 27(5)401-10.
Score: 0.543
RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
Marius Grzelinski ... Achim Aigner
Hum Gene Ther 2006 Jul; 17(7)751-66.
Score: 0.543
Competition for RISC binding predicts in vitro potency of siRNA.
Erich Koller ... Nicholas M Dean
Nucleic Acids Res 2006 ; 34(16)4467-76.
Score: 0.541
Expediting target identification and validation through RNAi.
Jens Kurreck
Expert Opin Biol Ther 2004 Mar; 4(3)427-9.
Score: 0.540
RNA interference silencing the transcriptional message: aspects and applications.
Shantanu Karkare ... Deepak Bhatnagar
Appl Biochem Biotechnol 2004 Oct; 119(1)1-12.
Score: 0.539
siRNA therapeutics: big potential from small RNAs.
R C C Ryther ... J G Patton
Gene Ther 2005 Jan; 12(1)5-11.
Score: 0.539
RNA interference as a potential tool in the treatment of leukaemia.
Arndt Borkhardt ... Olaf Heidenreich
Expert Opin Biol Ther 2004 Dec; 4(12)1921-9.
Score: 0.537
RNA interference and the use of small interfering RNA to study gene function in mammalian systems.
I Bantounas ... J B Uney
J Mol Endocrinol 2004 Dec; 33(3)545-57.
Score: 0.536
siRNA-based approaches in cancer therapy.
G R Devi
Cancer Gene Ther 2006 Sep; 13(9)819-29.
Score: 0.536
Targeted delivery systems of small interfering RNA by systemic administration.
Shigeru Kawakami ... Mitsuru Hashida
Drug Metab Pharmacokinet 2007 Jun; 22(3)142-51.
Score: 0.536
Molecular biology. Targeting intron insertion into DNA.
E Strauss
Science 2000 Jul; 289(5478)374.
Score: 0.536
Delivery of RNA interference.
Charles X Li ... Johannes H Fruehauf
Cell Cycle 2006 Sep; 5(18)2103-9.
Score: 0.535
A simple and cost-effective method for producing small interfering RNAs with high efficacy.
Muhammad Sohail ... Edwin M Southern
Nucleic Acids Res 2003 Apr; 31(7)e38.
Score: 0.535
RNAi: a novel antisense technology and its therapeutic potential.
Anne Dallas ... Alexander V Vlassov
Med Sci Monit 2006 Apr; 12(4)RA67-74.
Score: 0.535
Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3'-ends of siRNAs.
Makiko Hamada ... Kazunari Taira
Antisense Nucleic Acid Drug Dev 2002 Oct; 12(5)301-9.
Score: 0.534
RNA interference for the identification of disease-associated genes.
Alessio Nencioni ... Luk Van Parijs
Curr Opin Mol Ther 2004 Apr; 6(2)136-40.
Score: 0.533
Reovirus-specific ribonucleic acid from polysomes of infected L cells.
R Ward ... A J Shatkin
J Virol 1972 Jan; 9(1)61-9.
Score: 0.533
Silencing of disease-related genes by small interfering RNAs.
U Fuchs ... A Borkhardt
Curr Mol Med 2004 Aug; 4(5)507-17.
Score: 0.532
RNAi therapy for HIV infection: principles and practicalities.
Yamina Bennasser ... Kuan-Teh Jeang
BioDrugs 2007 ; 21(1)17-22.
Score: 0.532
Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
Bin Liu
Brief Funct Genomic Proteomic 2007 Jun; 6(2)112-9.
Score: 0.531
Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4.
N Zhou ... R J Pomerantz
Gene Ther 2004 Dec; 11(23)1703-12.
Score: 0.530
Modulation of gene expression by RNAi.
Cezary Wójcik ... George N DeMartino
Methods Mol Med 2005 ; 108()381-93.
Score: 0.530
In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
M Golzio ... J Teissié
Gene Ther 2007 May; 14(9)752-9.
Score: 0.530
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.
Jürgen Soutschek ... Hans-Peter Vornlocher
Nature 2004 Nov; 432(7014)173-8.
Score: 0.530
Failed to fetch article title! Article may not be available.
Score: 0.530
Lentiviral-mediated delivery of siRNAs for antiviral therapy.
K V Morris ... J J Rossi
Gene Ther 2006 Mar; 13(6)553-8.
Score: 0.530
The silent revolution: RNA interference as basic biology, research tool, and therapeutic.
Derek M Dykxhoorn ... Judy Lieberman
Annu Rev Med 2005 ; 56()401-23.
Score: 0.529
The use of small interfering RNA to elucidate the activity and function of ion channel genes in an intact tissue.
Alison M Gurney ... Elaine Hunter
J Pharmacol Toxicol Methods 2005 May-Jun; 51(3)253-62.
Score: 0.529
Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC.
Daniela Castanotto ... John J Rossi
Nucleic Acids Res 2007 ; 35(15)5154-64.
Score: 0.527
Functional comparison of single- and double-stranded siRNAs in mammalian cells.
Yunhe Xu ... Zicai Liang
Biochem Biophys Res Commun 2004 Apr; 316(3)680-7.
Score: 0.526
Chemical modification of gene silencing oligonucleotides for drug discovery and development.
Xiaolan Chen ... Jui H Wang
Drug Discov Today 2005 Apr; 10(8)587-93.
Score: 0.525
Short interfering RNAs as a tool for cancer gene therapy.
Marta Izquierdo
Cancer Gene Ther 2005 Mar; 12(3)217-27.
Score: 0.524
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells.
Frank Czauderna ... Jörg Kaufmann
Nucleic Acids Res 2003 Jun; 31(11)2705-16.
Score: 0.524
RNA interference (RNAi) in hematology.
M Scherr ... M Eder
Ann Hematol 2004 Jan; 83(1)1-8.
Score: 0.524
The silent treatment: siRNAs as small molecule drugs.
D M Dykxhoorn ... J Lieberman
Gene Ther 2006 Mar; 13(6)541-52.
Score: 0.524
Methylation of Herpesvirus saimiri DNA in lymphoid tumor cell lines.
R C Desrosiers ... B Fleckenstein
Proc Natl Acad Sci U S A 1979 Aug; 76(8)3839-43.
Score: 0.523
RNA interference: biology, mechanism, and applications.
Neema Agrawal ... Sunil K Mukherjee
Microbiol Mol Biol Rev 2003 Dec; 67(4)657-85.
Score: 0.523
Interfering with disease: opportunities and roadblocks to harnessing RNA interference.
Judy Lieberman ... Premlata Shankar
Trends Mol Med 2003 Sep; 9(9)397-403.
Score: 0.522
Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum.
Jörg Haupenthal ... Albrecht Piiper
Biochem Pharmacol 2006 Feb; 71(5)702-10.
Score: 0.520
Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection.
Kevin V Morris ... John J Rossi
Hum Gene Ther 2006 May; 17(5)479-86.
Score: 0.519
Recombinant Dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing.
Jason W Myers ... James E Ferrell
Nat Biotechnol 2003 Mar; 21(3)324-8.
Score: 0.519
Potential design rules and enzymatic synthesis of siRNAs.
Mouldy Sioud ... Marianne Leirdal
Methods Mol Biol 2004 ; 252()457-69.
Score: 0.518
Inhibition of human cytomegalovirus replication by small interfering RNAs.
Lüder Wiebusch ... Christian Hagemeier
J Gen Virol 2004 Jan; 85(Pt 1)179-84.
Score: 0.518
In silico selection of active siRNA.
Volker Patzel
Drug Discov Today 2007 Feb; 12(3-4)139-48.
Score: 0.518
Recognition of chromosomal DNA in human cells by peptide nucleic acids and small duplex RNAs.
David R Corey
Ann N Y Acad Sci 2005 Nov; 1058()16-25.
Score: 0.518
Selective silencing of viral gene E6 and E7 expression in HPV-positive human cervical carcinoma cells using small interfering RNAs.
Ming Jiang ... Jo Milner
Methods Mol Biol 2005 ; 292()401-20.
Score: 0.517
Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Lloyd R Kelland
Eur J Cancer 2005 May; 41(7)971-9.
Score: 0.517
Abstract:
Research Interests
Chemical Biology of Nucleic Acids
Design, synthesis and evaluation of novel gene targeting drugs.
The recent completion of the human genome project (HGP) revealed that there are 20,000-25,000 protein-coding genes. However, the experimental and computational annotation of human genome have shown that among the family of 3000 or more disease related genes, only 600-1000 genes can be targeted with small molecule drugs. This small number of genes and their corresponding protein products constitute the real “drug targets” in the human genome. However to find a small molecule drug against those disease related genes/proteins, which is the basis of traditional drug discovery approach, is increasingly difficult and that is clearly evident in the very slow progress being made in this area in recent times. It has been estimated that it takes 15 years of research and billions of US dollars to develop a protein targeting small molecule drug. Therefore, instead of targeting the protein itself if we can target gene (DNA) or the intermediate messenger RNA (mRNA) by a short oligonucleotide complementary to the target sequence, it is possible to stop the protein production. This provides ample opportunity to specifically target any disease causing gene, even if it’s undruggable by conventional medicine. The hypothesis was first validated by using antisense oligonucleotides targeting viral RNAs in 1978. Although enormous amount of research has been devoted to the development of antisense-based drugs, there are still problems remaining in terms of potency, specificity and delivery of these molecules inside cells and tissues. As a result there is an urgent need for employing alternate mechanisms and tools for efficient gene down-regulation. Our research efforts will be focused along this direction where we will be addressing the search for bona fide gene silencing molecules using three different approaches, which have emerged in the last decade: (1) Small interfering RNAs (siRNAs), (2) DNA enzymes, and (3) G-quadruplex stabilizing agents. All the projects are interrelated to each other, and demand a multidisciplinary chemical biology approach utilizing the tools from organic chemistry, biochemistry, biophysics and cell biology.
1)Development of chemically modified small interfering RNAs (siRNAs) as therapeutic agents .
The discovery of RNA interference (RNAi, Nobel Prize 2006), which is a post transcriptional gene silencing mechanism in mammalian cells using small interfering RNA (siRNA) duplexes revolutionized the field of gene targeted drugs in 2001. Unlike the antisense mechanism, RNAi is an evolutionarily conserved natural mechanism and has been shown to be more potent, specific and versatile to the mRNA targets, and thus provides enormous opportunity for rational drug discovery. Within the short span of time four RNAi based drugs have entered in the clinical trials and one is being evaluated in the Phase III stage. Chemist’s intervention is needed for making therapeutically appealing siRNAs for increasing their in vivo stability, potency, delivery and pharmacokinetic properties. However, finding a chemical modification (at the nucleotide level of siRNA) which will impart the required drug-like properties of siRNAs is a daunting task. To address such challenges, our lab will be focusing on the synthesis and evaluation of novel chemically modified siRNAs.
2)Selection and evaluation of novel RNA cleaving DNA enzymes.
Another gene silencing technology that emerged in the last decade is the use of DNA enzymes to cleave disease causing mRNAs. DNA enzymes are catalysts based entirely on DNA molecules and have been identified through a combinatorial biology technique called in vitro selection. In contrast to the action of antisense oligonucleotides or siRNAs, the catalytic activity of DNA enzymes does not require the recruitment of any cellular enzymes. Only cofactor needed for their activity is divalent metal ions such as Mg2+, Ca2+ or Zn2+. We will be employing in vitro selections to identify new enzymes that are more efficient than current ones. The lead sequences from such selection efforts will be fine tuned using chemical modifications in the binding arms and/or catalytic core to impart the exo and endonuclease stability, pharmacokinetic properties and in vivo deliverability.
3)Telomere mediated molecular therapeutics.
Telomere is a DNA-protein complex at the chromosomal ends having hexanucleotide repeats of sequence (TTAGGG) which prevents chromosomal degradation and fusion. The G-rich single stranded sequence at the 3’-end of telomere DNA can adopt varying tertiary structures including G-quadruplexes. In normal cells, after each cell division, the telomere sequence gets shortened and that leads to halting of cell division (senescence) and eventually controlled cell death (apoptosis). However, it has been demonstrated that in 85% of cancer cells an enzyme called telomerase is over expressed, which prevents natural shortening of telomere and leads to cell proliferation. Inhibition of telomerase action is an efficient way to tune back the cancer cells for natural cell death. One prominent strategy that emerged in last decade for telomerase inhibition is the stabilization of G-quadruplex structures of telomere DNA, thus preventing its availability as a primer for telomerase assisted elongation. The main criterion for a potential G-quadruplex stabilizing agent is that it should have high binding selectivity towards the intramolecular G-quadruplex structure of telomere over a DNA duplex structure or other potential quadruplex forming sequences in the genome. Only very few of the previously investigated compounds had shown specific inhibition of telomerase using nanomolar concentration (reflected in EC50 values). Therefore there is a large therapeutic window available for the development of novel G-quadruplex stabilizing agents. We will synthesize new quadruplex stabilizing agents and study their interaction with telomeric DNAs.
Keywords extracted from the abstract:
[ eliminated words list ]
Count
Word
6.000
000-25
6.000
1
6.000
2
6.000
3
6.000
3’-end
6.000
600-1000
1.091
acids
2.869
action
1.702
activity
2.309
address
2.916
addressing
2.994
adopt
1.767
agent
3.097
agents
2.762
alternate
1.708
amount
3.609
ample
3.526
annotation
6.024
antisense
5.368
antisense-based
1.532
apoptosis
3.799
appealing
2.838
approach
1.964
approaches
1.424
area
2.682
arms
2.480
assisted
2.122
availability
1.577
available
2.082
back
Count
Word
2.692
based
1.584
basis
4.282
billions
2.058
binding
1.642
biochemistry
4.725
biology
2.285
biophysics
3.570
bona
1.510
ca2
4.581
called
1.968
cancer
3.195
catalysts
4.097
catalytic
4.450
causing
2.668
cell
2.258
cells
1.428
cellular
2.429
challenges
4.406
chemical
2.877
chemically
0.927
chemistry
6.000
chemist’s
4.211
chromosomal
1.992
clearly
3.187
cleave
3.401
cleaving
0.816
clinical
2.674
cofactor
2.988
combinatorial
1.847
complementary
Count
Word
2.507
completion
1.242
complex
1.313
compounds
2.636
computational
1.143
concentration
1.910
conserved
2.511
constitute
1.331
contrast
1.404
controlled
1.757
conventional
1.925
core
1.730
corresponding
2.538
criterion
1.462
current
4.211
daunting
2.801
death
6.641
decade
1.829
degradation
5.455
deliverability
3.333
delivery
2.334
demand
1.310
demonstrated
1.430
design
1.851
develop
2.725
development
3.153
devoted
1.008
different
1.926
difficult
2.174
direction
6.497
discovery
Count
Word
2.583
disease
2.505
divalent
2.735
division
4.113
dna
3.366
dna-protein
2.834
dnas
3.021
dollars
2.386
down-regulation
1.938
drug
4.392
drug-like
5.082
drugs
2.527
duplex
3.314
duplexes
2.831
ec50
5.411
efficient
4.629
efforts
2.377
elongation
7.018
emerged
5.160
employing
2.690
endonuclease
2.512
ends
6.462
enormous
2.563
entered
2.623
entirely
1.140
enzyme
6.793
enzymes
1.793
estimated
1.432
evaluated
3.380
evaluation
1.556
even
Count
Word
2.604
eventually
3.129
evolutionarily
3.851
exo
1.303
experimental
1.417
expressed
1.248
family
3.768
fide
1.656
field
1.912
finding
2.325
fine
1.109
first
2.337
focused
2.375
focusing
2.389
forming
1.613
fusion
15.689
g-quadruplex
5.022
g-quadruplexes
4.196
g-rich
4.109
gene
4.188
genes
5.898
genome
3.542
gets
4.197
halting
1.775
having
4.189
hexanucleotide
4.037
hgp
0.994
high
1.355
human
1.717
hypothesis
1.307
identified
Count
Word
1.705
identify
1.540
iii
7.695
impart
1.327
including
1.571
increasing
2.377
increasingly
3.531
inhibition
1.505
interaction
3.028
interests
2.326
interference
7.612
interfering
1.897
intermediate
3.422
interrelated
1.767
intervention
2.747
intramolecular
1.332
investigated
1.991
ions
6.000
it’s
2.175
lab
1.349
large
5.122
last
1.645
lead
3.917
leads
1.171
level
1.499
made
1.617
main
1.915
making
1.879
mammalian
3.788
mechanism
1.429
mechanisms
Count
Word
1.739
mediated
0.871
medicine
1.470
messenger
2.075
metal
2.387
mg2
1.989
modification
2.266
modifications
3.550
modified
0.946
molecular
5.082
molecule
4.369
molecules
2.457
more
2.826
mrna
2.259
mrnas
2.746
multidisciplinary
3.239
nanomolar
4.482
natural
1.656
need
3.812
needed
3.369
nobel
1.028
normal
5.011
novel
1.694
nucleic
1.875
nucleotide
2.255
oligonucleotide
4.618
oligonucleotides
2.315
ones
2.673
only
5.144
opportunity
1.989
organic
Count
Word
1.884
other
4.709
pharmacokinetic
1.363
phase
1.333
possible
2.245
post
4.520
potency
1.815
potent
2.627
potential
2.250
preventing
4.950
prevents
1.415
previously
2.548
primer
3.449
prize
1.589
problems
1.322
production
1.589
products
2.146
progress
2.119
project
2.355
projects
1.617
proliferation
2.280
prominent
3.880
properties
2.275
protein
3.632
protein-coding
0.711
proteins
3.595
provides
8.179
quadruplex
2.657
rational
2.366
real
3.161
recent
Count
Word
2.342
recruitment
2.375
reflected
2.610
related
1.966
remaining
2.300
repeats
2.003
require
1.432
required
1.318
revealed
3.816
revolutionized
3.456
rna
9.237
rnai
6.991
rnas
2.137
search
4.717
selection
3.786
selections
2.351
selectivity
2.920
senescence
2.935
sequence
3.119
sequences
3.540
short
2.724
shortened
2.479
shortening
7.642
silencing
1.329
single
7.269
sirna
15.447
sirnas
1.988
slow
5.483
small
2.652
span
2.394
specific
Count
Word
1.887
specifically
1.347
specificity
3.655
stability
2.432
stabilization
9.337
stabilizing
1.511
stage
2.641
stop
3.422
stranded
1.997
strategy
2.624
structure
3.327
structures
2.523
synthesis
2.728
synthesize
2.515
takes
4.468
target
4.710
targeted
7.327
targeting
2.126
targets
6.000
targets”
1.976
task
1.323
technique
1.696
technology
9.248
telomerase
11.997
telomere
2.991
telomeric
1.846
terms
2.214
tertiary
1.746
therapeutic
3.188
therapeutically
2.545
therapeutics
Count
Word
0.915
time
1.512
times
1.518
tissues
4.795
tools
2.037
towards
2.057
traditional
1.961
transcriptional
1.502
trials
4.093
ttaggg
3.939
tune
3.396
tuned
6.000
undruggable
2.317
unlike
2.849
urgent
0.916
us
3.247
using
2.431
utilizing
2.519
validated
1.252
values
2.156
varying
3.127
versatile
1.198
viral
2.232
vitro
2.755
vivo
1.932
way
2.690
window
1.053
years
3.021
zn2
6.000
“drug
RIC Statistics:
Extraction Method: Keyword Count with Lexical Variants Added
Eliminated words list: MedlinePlus List
Similarity Method: Weighted keyword count
Weighting Method: Term Frequency * Inverse Document Frequency
Database: Medline abstracts (1967 - Present)
Publication Type: All
Score Calculation Method: Cosine Similarity Method
Sort by: Score
Submission date and time: 2-22-2008, 23:37:39
Computation time: 00:00:04
Last updated: Friday, 22-Feb-2008 23:37:43 CST